Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Mol Cancer Ther. 2016 Feb 1;15(3):402–411. doi: 10.1158/1535-7163.MCT-15-0644

Figure 4.

Figure 4

Inhibitory effects by the integrated therapy of Ad/HER2-ECD and Tra-IR700–mediated PIT in vivo. A, mice peritoneally bearing MKN45 cells were treated with or without Ad/HER2-ECD (1×108 pfu) and/or Tra-IR700 (80 µg) on days 5 and 7 after tumor injection, respectively. All groups except for the control group were irradiated with NIR light at 50 J/cm2. All mice were sacrificed on day 28 after tumor injection, and the total weight of peritoneal tumors in each mouse were measured. The tumor weight of the integrated therapy group (n= 4, Ad+IR+PIT; 0.50±0.06 g) was significantly lower than that of the other condition groups (n= 4, control; 1.32±0.58 g, IR+PIT; 1.10±0.29 g, Ad+PIT; 1.07±0.35 g: Student’s t-test, *P< 0.05). B, the survival of mice with peritoneal dissemination after the integrated therapy. The survival curve showed that the integrated therapy led to the significantly prolonged survival of mice with peritoneal dissemination as compared with controls (n= 5 mice in each treatment group; *P< 0.05 vs the other control group using a log-rank test).